Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmuPharma PLC (GB:IMM)
LSE:IMM
Holding GB:IMM?
Track your performance easily
IMM Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range0.82p - 3.00p
Previous Close1.69p
Volume3.43M
Average Volume (3M)1.29M
Market Cap
£7.04M
Enterprise Value6.37M
Total Cash (Recent Filing)£667.81K
Total Debt (Recent Filing)£111.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
May 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding416,440,000
10 Day Avg. Volume1,052,852
30 Day Avg. Volume1,294,227
Standard Deviation0.29
R-Squared0.12
Alpha-0.00720
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)95.24
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ImmuPharma News
PremiumCompany Announcements
ImmuPharma Extends Incanthera Warrants to 2025
PremiumCompany Announcements
ImmuPharma Shows Strong Progress and Reduced Losses
PremiumCompany Announcements
ImmuPharma Share Ownership Shift Notified
PremiumCompany Announcements
ImmuPharma Gains Full Support at AGM
PremiumCompany Announcements
ImmuPharma Schedules AGM, Shares Annual Report
PremiumCompany Announcements
ImmuPharma Announces Progress and Reduced LossesPremiumCompany Announcements
ImmuPharma Realizes £1.5 Million from Share Sale
PremiumCompany Announcements
ImmuPharma Major Shareholding Shift NotedOptions Prices
Currently, No data available
---
Ownership Overview
9.20%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
90.80% Public Companies and
Individual Investors
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 0.82p and its highest was 3.00p in the past 12 months.
What is ImmuPharma PLC’s market cap?
Currently, no data Available
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is May 22, 2025 which is in 244 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on Sep 09, 2024. The company reported -0.001p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001p.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC does not currently pay dividends.
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 416,437,260 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of -0.001p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.247%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
---
ImmuPharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.54%
Trailing 12-Months
Company Description
ImmuPharma PLC
ImmuPharma PLC is a drug discovery and development company. The company is focused on the development of drugs based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. It has drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the company's drug candidate and is a treatment for lupus, and life-threatening autoimmune disease. The company's pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity; Anti-Infectives; Metabolism and Cancer.
---
Technical Analysis
---